J&J Q2 Results: Pharma major beats Wall Street estimates on strong drug sales

Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.